← Back to Search
Suppression, Subversion And Escape: The Role Of Regulatory T Cells In Cancer Progression
K. Oleinika, R. Nibbs, G. Graham, A. R. Fraser
Published 2013 · Biology, Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
Regulatory T cells (Tregs) are crucial in mediating immune homeostasis and promoting the establishment and maintenance of peripheral tolerance. However, in the context of cancer their role is more complex, and they are thought to contribute to the progress of many tumours. As cancer cells express both self‐ and tumour‐associated antigens, Tregs are key to dampening effector cell responses, and therefore represent one of the main obstacles to effective anti‐tumour responses. Suppression mechanisms employed by Tregs are thought to contribute significantly to the failure of current therapies that rely on induction or potentiation of anti‐tumour responses. This review will focus on the current evidence supporting the central role of Tregs in establishing tumour‐specific tolerance and promoting cancer escape. We outline the mechanisms underlying their suppressive function and discuss the potential routes of Tregs accumulation within the tumour, including enhanced recruitment, in‐situ or local proliferation, and de‐novo differentiation. In addition, we review some of the cancer treatment strategies that act, at least in part, to eliminate or interfere with the function of Tregs. The role of Tregs is being recognized increasingly in cancer, and controlling the function of these suppressive cells in the tumour microenvironment without compromising peripheral tolerance represents a significant challenge for cancer therapies.
This paper references
Expression of Helios, an Ikaros Transcription Factor Family Member, Differentiates Thymic-Derived from Peripherally Induced Foxp3+ T Regulatory Cells
A. Thornton (2010)
Administration of a CD 25 - directed immunotoxin , LMB - 2 , to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo
DJ Powell (2007)
Targeting regulatory T cells
C. Ménétrier-Caux (2012)
CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3[+] regulatory T cells in gastric cancer
水上 佳樹 (2008)
Improved survival with ipilimumab in patients with metastatic melanoma.
F. S. Hodi (2010)
Brain cancer immunoediting: novel examples provided by immunotherapy of malignant gliomas
S. Pellegatta (2011)
Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection.
Q. Gao (2007)
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication
S. Quezada (2011)
Conversion of Peripheral CD4+CD25− Naive T Cells to CD4+CD25+ Regulatory T Cells by TGF-β Induction of Transcription Factor Foxp3
W. Chen (2003)
Increased Intratumoral FOXP 3 - positive regulatory immune cells during interleukin - 2 treatment in metastatic renal cell carcinoma
HK Jensen (2009)
Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo
X. Zhou (2009)
Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide.
G. Maclean (1996)
Immune response to syngeneic or autologous testicular cells in mice. I. Augmented delayed footpad reaction in cyclophosphamide-treated mice.
S. Yoshida (1979)
T cell lineage in vivo
MA Gavin (2010)
Human leukocyte antigen class I , MHC class I chain - related molecule A , and CD 8 ( + ) / regulatory T - cell ratio : which variable determines survival of cervical cancer patients ?
ES Jordanova (2008)
Specific recruitment of CC chem
T Ishida (2000)
Heterogeneity of natural Foxp3+ T cells: A committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity
N. Komatsu (2009)
Tumor cells convert imma
F Ghiringhelli (2009)
Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor.
M. Miyara (2009)
Conversion of peripheral CD 4 ( + ) CD 25 ( – ) naive T cells to CD 4 ( + ) CD 25 ( + ) regulatory T cells by TGF - beta induction of transcription factor Foxp 3
WJ Chen (2003)
Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody.
S. Onizuka (1999)
Clinical Use of Anti‐CD25 Antibody Daclizumab to Enhance Immune Responses to Tumor Antigen Vaccination by Targeting Regulatory T cells
Andrew J. Rech (2009)
Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege.
T. Ishida (2006)
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired.
M. Ahmadzadeh (2009)
Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma.
L. Ormandy (2005)
British Society for Immunology
E. Langer (1957)
Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity.
J. Shimizu (1999)
Two modes of immune suppression by Foxp3(+) regulatory T cells under inflammatory or non-inflammatory conditions.
T. Yamaguchi (2011)
Response to Comment on “Analysis of the Cellular Mechanism of Antitumor Responses and Autoimmunity in Patients Treated with CTLA-4 Blockade”
S. Rosenberg (2006)
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival
T. Curiel (2004)
Plasticity of Foxp 3 ( + ) T cells reflects promiscuous Foxp 3 expression in conventional T cells but not reprogramming of regulatory T cells
T Miyao (2012)
Induction of tumor immunity
J Shimizu (2011)
Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens
Denise Golgher (2002)
CD 25 ( + ) regulatory T cell depletion augments immunotherapy of micrometastases by an IL - 21 - secreting cellular vaccine
A Comes (2006)
CCL17 and CCL22 chemokines within tumor microenvironment are related to infiltration of regulatory T cells in esophageal squamous cell carcinoma.
T. Maruyama (2010)
Natural Regulatory T Cells and De Novo-Induced Regulatory T Cells Contribute Independently to Tumor-Specific Tolerance1
G. Zhou (2007)
predicts reduced survival
M Gobert (2004)
Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase.
M. Sharma (2007)
CD25(+) T regulatory cells: role of tumor-derived TGF-beta
A critical analysis of the tumour immunosurveillance controversy for 3-MCA-induced sarcomas
T. Schreiber (2009)
Adoptive transfer of T(reg) depleted autologous T cells in advanced renal cell carcinoma.
F. Thistlethwaite (2008)
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
R. Schreiber (2011)
Tumor Evasion of the Immune System by Converting CD4+CD25− T Cells into CD4+CD25+ T Regulatory Cells: Role of Tumor-Derived TGF-β
V. Liu (2007)
Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival
R. Griffiths (2007)
Nature of immunosuppressor
MI Greene (2006)
Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse.
G. Bates (2006)
Tumor infiltrating Foxp3+ regulatory T‐cells are associated with recurrence in pathologic stage I NSCLC patients
R. Petersen (2006)
T-regulatory cell modulation: the future of cancer immunotherapy?
S. Nizar (2009)
K Nosho (2009)
Unique chemotactic response
A Iellem (2006)
Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells.
A. Curti (2007)
Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells.
D. Berd (1988)
Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer
S. Ladoire (2011)
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells.
S. Quezada (2006)
Disruption of CCR5
MCB Tan (2011)
Hallmarks of Cancer: The Next Generation
D. Hanahan (2011)
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells
J. Fontenot (2003)
Comment on “Analysis of the Cellular Mechanism of Antitumor Responses and Autoimmunity in Patients Treated with CTLA-4 Blockade”
D. O'Mahony (2006)
Adaptive immunity maintains occult cancer in an equilibrium state
Catherine M. Koebel (2007)
Tumour‐infiltrating T‐cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review
K. Nosho (2010)
CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma.
R. Talpur (2006)
Prognostic value of tumor - infiltrating CD 4 ( + ) T - cell subpopulations in head and neck cancers
C Badoual (2006)
TJ Curiel (2010)
CCL 17 and CCL 22 chemokines within tumor microenvironment are related to infiltration of regulatory T cells in esophageal squamous cell carcinoma
T Maruyama (2010)
pathologic stage INSCLC patients
Q Gao (2006)
Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
F. Ghiringhelli (2006)
Disruption of CCR 5 - dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer
Tan MCB (2009)
tumors to be curative
D Berd (2004)
Analysis of the Cellular Mechanism of Antitumor Responses and Autoimmunity in Patients Treated with CTLA-4 Blockade
A. Maker (2005)
Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy.
L. Zhang (2008)
Unique Chemotactic Response Profile and Specific Expression of Chemokine Receptors Ccr4 and Ccr8 by Cd4+Cd25+ Regulatory T Cells
A. Iellem (2001)
Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development.
M. Gavin (2006)
Intratumoural FOXP 3 - positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer
G Perrone (2008)
IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients.
M. Ahmadzadeh (2006)
Suppression of tumour-specific CD4+ T cells by regulatory T cells is associated with progression of human colorectal cancer
G. Betts (2011)
Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells.
J. Dannull (2005)
Dendritic Cells Loaded with Stressed Tumor Cells Elicit Long-Lasting Protective Tumor Immunity in Mice Depleted of CD4+CD25+ Regulatory T Cells1
S. Prasad (2005)
Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade.
A. Hurwitz (2000)
Cloning and characterization of GITR ligand
J. Kim (2003)
Plasticity of Foxp3(+) T cells reflects promiscuous Foxp3 expression in conventional T cells but not reprogramming of regulatory T cells.
Takahisa Miyao (2012)
Different subsets of tumor infiltrat
YL Zhang (2006)
CD 8 + T cell immunity against a tumor / self - antigen is augmented by CD 4 ( + ) T helper cells and hindered by naturally occurring T regulatory cells
PA Antony (2005)
R. Tsang (2006)
Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability.
F. Colotta (2009)
T lymphocytes infiltrating sites of tumor rejection and progression display identical V beta usage but different cytotoxic activities.
R. Kurt (1995)
Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin’s lymphoma
A. Tzankov (2008)
Inability of a Fusion Protein of IL-2 and Diphtheria Toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to Eliminate Regulatory T Lymphocytes in Patients With Melanoma
P. Attia (2005)
A role for the transcription factor Helios in human CD 4 ( + ) CD 25 ( + ) regulatory T cells
D Getnet (2010)
Expression of helios
AM Thornton (2010)
Brain cancer immunoedit
S Pellegatta (2009)
Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer.
P. Salama (2009)
Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance
G. Willimsky (2005)
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
A. Facciabene (2011)
Inability to Mediate Prolonged Reduction of Regulatory T Cells After Transfer of Autologous CD25-depleted PBMC and Interleukin-2 After Lymphodepleting Chemotherapy
D. Powell (2007)
Prognostic Value of Tumor-Infiltrating CD4+ T-Cell Subpopulations in Head and Neck Cancers
C. Badoual (2006)
Mice Bearing Late-Stage Tumors Have Normal Functional Systemic T Cell Responses In Vitro and In Vivo1
S. Radoja (2000)
Human Leukocyte Antigen Class I, MHC Class I Chain-Related Molecule A, and CD8+/Regulatory T-Cell Ratio: Which Variable Determines Survival of Cervical Cancer Patients?
E. Jordanova (2008)
Modulation of tryptophan
A Curti (2007)
Regualtion of the immune response to tumor antigens. I. Immunosuppressor cells in tumor-bearing hosts.
S. Fujimoto (1976)
Different subsets of tumor infiltrating lymphocytes correlate with NPC progression in different ways
Y. Zhang (2009)
FoxP3 transcription factor
T Miyao (2009)
Expanded subpopulation of FoxP3+ T regulatory cells in renal cell carcinoma co-express Helios, indicating they could be derived from natural but not induced Tregs.
E. Elkord (2011)
Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.
S. Sakaguchi (1995)
Enhancement of Antitumor Immunity by CTLA-4 Blockade
D. Leach (1996)
Cancer immunoediting: from immunosurveillance to tumor escape
Gavin P Dunn (2002)
Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells
K. Ko (2005)
CD8+ T Cell Immunity Against a Tumor/Self-Antigen Is Augmented by CD4+ T Helper Cells and Hindered by Naturally Occurring T Regulatory Cells
P. Antony (2005)
Metronomic chemotherapy enhances antitumor effects of cancer vaccine by depleting regulatory T lymphocytes and inhibiting tumor angiogenesis.
Chi-An Chen (2010)
Tumor-induced expansion of regulatory T cells by conversion of CD4+CD25- lymphocytes is thymus and proliferation independent.
B. Valzasina (2006)
CD 25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T - cell lymphoma
R Talpur (2006)
CD25+ Regulatory T Cell Depletion Augments Immunotherapy of Micrometastases by an IL-21-Secreting Cellular Vaccine1
A. Comes (2006)
OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis
Daniel Hirschhorn-Cymerman (2009)
Intraepithelial CD8(+) tumor
E Sato (1996)
TCR v(beta) usage and clonality of T cells isolated from progressing and rejected tumor sites before and after in vitro culture.
R. Kurt (2000)
L. Yung (2003)
Disruption of CCR5-Dependent Homing of Regulatory T Cells Inhibits Tumor Growth in a Murine Model of Pancreatic Cancer1
M. Tan (2009)
Tumor cells convert immature myeloid dendritic cells into TGF-β–secreting cells inducing CD4+CD25+ regulatory T cell proliferation
F. Ghiringhelli (2005)
A Phase II Trial of Denileukin Diftitox in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer
M. Gerena-Lewis (2009)
Administration of a CD25-Directed Immunotoxin, LMB-2, to Patients with Metastatic Melanoma Induces a Selective Partial Reduction in Regulatory T Cells In Vivo1
D. Powell (2007)
Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide.
M. E. C. Lutsiak (2005)
The role of CD4+CD25+ immunoregulatory T cells in the induction of autoimmune gastritis
K. Laurie (2002)
CTLA 4 blockade and GM - CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells
MA Curran (2006)
CCL17 and CCL22 chemok
T Maruyama (2008)
Tumor evasion of the immune
VC Liu (2003)
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
J. Galon (2006)
Increase of CD4+CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+CD25+ T lymphocytes
S. Audia (2007)
Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study.
R. Lord (2007)
Prevalence of FOXP3+ Regulatory T Cells Increases During the Progression of Pancreatic Ductal Adenocarcinoma and Its Premalignant Lesions
N. Hiraoka (2006)
Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer.
G. Perrone (2008)
A role for the transcription factor Helios in human CD4(+)CD25(+) regulatory T cells.
D. Getnet (2010)
CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative
F. Ghiringhelli (2004)
The phase II trial.
R. Wittes (1985)
Nature of immunosuppressor T cells and their factors in tumor - bearing host ( Tbh )
MI Greene (1976)
Tumor infiltrating FOXP 3 ( + ) regulatory T - cells are associated with recurrence in pathologic stage INSCLC patients
RP Petersen (2006)
Stimulation of CD25+CD4+ regulatory T cells through GITR breaks immunological self-tolerance
J. Shimizu (2002)
Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model
Y. Eralp (2004)
Comparative analysis of regulatory and effector T cells in progressively growing versus rejecting tumors of similar origins.
J. Bui (2006)
Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy.
E. Kwon (1999)
Regulatory T cells, tumour immunity and immunotherapy
W. Zou (2006)
Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses
R. P. Sutmuller (2001)
M Miyara (2006)
T cells in vivo
YP Rubtsov (2009)
CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T cells in gastric cancer
Y. Mizukami (2008)
Increased Intratumoral FOXP3-positive Regulatory Immune Cells during Interleukin-2 Treatment in Metastatic Renal Cell Carcinoma
H. K. Jensen (2009)
A role for the transcrip
D Getnet (2011)
Stability of the Regulatory T Cell Lineage in Vivo
Y. Rubtsov (2010)
Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors.
M. Curran (2009)
Analysis of the T-cell receptor repertoires of tumor-infiltrating conventional and regulatory T cells reveals no evidence for conversion in carcinogen-induced tumors.
J. Hindley (2011)
Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome.
Michael Gobert (2009)
Concomitant Tumor Immunity to a Poorly Immunogenic Melanoma Is Prevented by Regulatory T Cells
M. Turk (2004)
Single-cell analysis of normal and FOXP 3-mutant human T cells : FOXP 3 expression without regulatory T cell development
M. Gavin (2006)
Increased regulatory T-cell numbers distinguish high-risk breast cancer patients and those at risk of late relapse
G. Bates (2006)
Intraepithelial CD 8 ( + ) tumor - infiltrating lymphocytes and a high CD 8 ( + ) / regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
E Sato (2005)
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.
E. Sato (2005)
Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma
C. Clemente (1996)
This paper is referenced by
Inflammasome Activation Is Critical to the Protective Immune Response during Chemically Induced Squamous Cell Carcinoma
T. H. Gasparoto (2014)
Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells
Fengtao You (2016)
Cancer acidity: An ultimate frontier of tumor immune escape and a novel target of immunomodulation.
V. Huber (2017)
Breast cancer cell–derived IL-35 promotes tumor progression via induction of IL-35-producing induced regulatory T cells
Shengnan Hao (2018)
B cell regulation in cancer and anti-tumor immunity
Anushruti Sarvaria (2017)
Potential Immune Biomarkers in Gastrointestinal Cancers: Immune Inhibitory Molecules, Lymphocytes and Tumor Antigens
K. Sideras (2017)
Assessment of cytokine mRNA expression profiles in tumor microenvironment and peripheral blood mononuclear cells of patients with high-grade serous carcinoma of the ovary
Pernilla Israelsson (2017)
Natural and Induced T Regulatory Cells in Cancer
Dennis O. Adeegbe (2013)
Rational combination with an immunotherapy backbone in genitourinary cancers
Jhe-Cyuan Guo (2020)
Xihuang pill promotes apoptosis of Treg cells in the tumor microenvironment in 4T1 mouse breast cancer by upregulating MEKK1/SEK1/JNK1/AP-1 pathway.
L. Su (2018)
Secretory High-Mobility Group Box 1 Protein Affects Regulatory T Cell Differentiation in Neuroblastoma Microenvironment In Vitro
Thitinee Vanichapol (2018)
Cancer Risk and Multiple Sclerosis: Evidence From a Large Italian Cohort
E. D’Amico (2019)
Stem cell technology and engineering for cancer treatment
S. N. Truong (2015)
Vascular related pathologies in cardiovascular disease and cancer
S. Ananthaseshan (2018)
Metastatic mechanisms in follicular cell-derived thyroid cancer.
J. Phay (2013)
Immunohistochemical Analysis of Foxp3+, CD4+, CD8+ Cell Infiltrates and PD-L1 in Oral Squamous Cell Carcinoma
O. Stasikowska-Kanicka (2017)
Atezolizumab for use in PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast cancer.
A. Mavratzas (2019)
T cell receptor mimic antibodies for cancer therapy
Leonid Dubrovsky (2016)
Suppressive Characteristics of Umbilical Cord Blood–derived Regulatory T Cells After Ex Vivo Expansion on Autologous and Allogeneic T Effectors and Various Lymphoblastic Cells
Thitinee Vanichapol (2019)
The role of glycosylation in regulatory T-cell biology
Faria Ferreira Cabral (2016)
Cancer Vaccines: Past, Present, and Future
S. Mohammed (2016)
Differences of the immune cell landscape between normal and tumor tissue in human prostate
E. Zhang (2019)
Mobilization with cyclophosphamide reduces the number of lymphocyte subpopulations in the leukapheresis product and delays their reconstitution after autologous hematopoietic stem cell transplantation in patients with multiple myeloma
M. Skerget (2016)
Cellular prognostic markers in hepatitis-related hepatocellular carcinoma
A. Petrizzo (2018)
Tumor abolition and antitumor immunostimulation by physico-chemical tumor ablation.
Y. Keisari (2017)
Implications of Immune-Mediated Metastatic Growth on Metastatic Dormancy, Blow-Up, Early Detection, and Treatment
Adam Rhodes (2019)
Classical Hodgkin Lymphoma with Positive Epstein-Barr Virus Status is Associated with More FOXP3 Regulatory T Cells
Antonia Pavlovic (2016)
Cancer specific risk in multiple sclerosis patients.
A. Kyritsis (2016)
IL-17 induces radiation resistance of B lymphoma cells by suppressing p53 expression and thereby inhibiting irradiation-triggered apoptosis
Qingshan Li (2015)
The role of IKKα during diet-induced obesity and glucose intolerance in insulin sensitive tissues. The role of glycosylation during intestinal carcinogenesis
Jessica Heringer (2014)
Intratumoral expression of FoxP3-positive regulatory T-cells in T-cell lymphoma: no correlation with survival
J. Lundberg (2019)
Antitumor activity of total flavonoids from Tetrastigma hemsleyanum Diels et Gilg is associated with the inhibition of regulatory T cells in mice
Zhengquan Feng (2014)See more